GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report)'s stock price was up 9.3% during mid-day trading on Tuesday . The stock traded as high as $93.09 and last traded at $92.62. Approximately 108,462 shares were traded during trading, a decline of 89% from the average daily volume of 1,020,420 shares. The stock had previously closed at $84.77.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. TD Cowen increased their price target on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their target price on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $72.33.
Get Our Latest Stock Report on GeneDx
GeneDx Price Performance
The stock has a market cap of $2.71 billion, a P/E ratio of -49.30 and a beta of 1.93. The business has a 50 day simple moving average of $90.43 and a 200-day simple moving average of $78.11. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.
GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, sell-side analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current year.
Insider Activity at GeneDx
In related news, CFO Kevin Feeley sold 922 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.72, for a total value of $87,331.84. Following the sale, the chief financial officer now directly owns 5,446 shares in the company, valued at approximately $515,845.12. The trade was a 14.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the transaction, the chief executive officer now owns 3,937 shares of the company's stock, valued at $308,975.76. This represents a 29.62 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 138,780 shares of company stock worth $12,907,437. Insiders own 27.30% of the company's stock.
Institutional Investors Weigh In On GeneDx
A number of hedge funds and other institutional investors have recently bought and sold shares of WGS. Barclays PLC raised its stake in shares of GeneDx by 346.3% during the 3rd quarter. Barclays PLC now owns 18,921 shares of the company's stock valued at $803,000 after purchasing an additional 14,681 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of GeneDx during the third quarter valued at about $325,000. Franklin Resources Inc. purchased a new stake in shares of GeneDx in the third quarter worth about $301,000. Prudential Financial Inc. bought a new position in shares of GeneDx in the fourth quarter valued at approximately $7,938,000. Finally, JPMorgan Chase & Co. grew its stake in GeneDx by 617.3% during the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company's stock valued at $2,214,000 after acquiring an additional 44,889 shares in the last quarter. Institutional investors own 61.72% of the company's stock.
GeneDx Company Profile
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
See Also
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
